Form SCHEDULE 13G Yarrow Bioscience, Inc. Filed by: venBio Global Strategic Fund V, L.P. Aug 14, 2026 04:41PM
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 13, 2026 07:00AM
Yarrow Bioscience completes VYNE merger, begins Phase 2a/2b trial Jul 27, 2026 07:00AM
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Jul 27, 2026 07:00AM